BP1001-A in Patients With Advanced or Recurrent Solid Tumors
← catalyst calendarNCT04196257 · readout ≤ 346 d
Sponsored by Bio-Path Holdings, Inc. (industry) · BPTH — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
50estimated
Sites
4
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-08-19 | actual | When the study began enrolling |
| Primary completion | Jul 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2019-12-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-03-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Solid Tumor, Adult
- Carcinoma, Ovarian Epithelial
- Fallopian Tube Neoplasms
- Endometrial Cancer
- Peritoneal Cancer
- Solid Tumor
Interventions
- Drug: BP1001-A (Liposomal Grb2 Antisense Oligonucleotide)
- Drug: BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel
Primary outcomes
what the primary-completion date above is the date OFIdentify Dose Limiting Toxicity (DLT) of BP1001-A
measured 30 days
Identify maximum tolerated dose (MTD) of BP1001-A
measured 30 days
Identify and grade Treatment-Emergent Adverse Events (TEAE) of BP1001-A
measured 30 days
Identify and grade Treatment-Emergent Adverse Events (TEAE) of BP1001-A in combination with paclitaxel
measured 30 days
Permalink · BPTH's whole pipeline · Catalyst calendar · Every registered study · What changed